Definium Therapeutics (DFTX) Cash & Equivalents (2020 - 2026)

Definium Therapeutics (DFTX) has 7 years of Cash & Equivalents data on file, last reported at $257.2 million in Q1 2026.

• Quarterly Cash & Equivalents rose 219.9% year-over-year to $257.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $257.2 million (up 219.9% YoY) and the FY2025 annual result came in at $255.3 million, down 5.97% from the prior year.
• Cash & Equivalents climbed to $257.2 million in Q1 2026 per DFTX's latest filing, from $255.3 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $295.3 million in Q3 2024 and bottomed at $20.0 million in Q3 2025.
• The 5-year median for Cash & Equivalents is $130.6 million (2022), against an average of $159.0 million.
• The widest annual swing landed in 2025, when Cash & Equivalents slumped 93.24%; it then soared 219.9% in 2026.
• Tracing DFTX's Cash & Equivalents over 5 years: stood at $131.7 million in 2022, then fell by 24.29% to $99.7 million in 2023, then jumped by 172.31% to $271.5 million in 2024, then dropped by 5.97% to $255.3 million in 2025, then rose by 0.74% to $257.2 million in 2026.
• Per Business Quant, the three latest DFTX Cash & Equivalents figures stand at $257.2 million (Q1 2026), $255.3 million (Q4 2025), and $20.0 million (Q3 2025).

Peer Comparison